J&J Remediates Two OTC Facilities To FDA Approval, Waits On Third
This article was originally published in The Tan Sheet
Executive Summary
Its headquarters plant was closed and production at two other facilities was slowed under a 2011 consent decree. J&J did not say when it expects FDA’s decision on the third plant.
You may also be interested in...
Missing CAPA Costs J&J $25 Million In Investigation Sparked By OTC Recalls
J&J/McNeil enter a guilty plea in federal court to a misdemeanor charge of distributing adulterated drugs and agree to pay a criminal fine of $20 million and forfeit $5 million. McNeil has submitted to FDA experts’ certifications of remediation processes being complete at its three facilities subject to a consent decree.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.